IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:) Examiner: O'Hara, Eileen B.
Audrey GODDARD, et al.) Art Unit: 1646
Application Serial No. 09/978,191) Confirmation No.: 4728
Filed: October 15, 2001) Attorney's Docket No.: 39780-2630 P1C4
For: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC ACIDS ENCODING THE SAME) Customer No. 35489))

EXPRESS MAIL LABEL NO. EL 993 635 649 US

DATE MAILED: MAY 23, 2005

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. §1.97

MAIL STOP RCE

Commissioner for Patents PO Box 1450 Alexandria, Virginia 22313-1450

Sir:

Listed below or on an attached Form PTO-1449 is information known to applicant(s). A copy of each listed publication and U.S. and foreign patent, except for pending U.S. applications, is being submitted herewith, along with a concise explanation of information in a foreign language, if any, pursuant to 37 C.F.R. §1.97-1.98.

Applicants respectfully request that the listed information be considered by the Examiner and be made of record in the above-identified application. If PTO-1449 is enclosed, the Examiner is requested to initial and return it in accordance with M.P.E.P. §609.

This statement is not intended to represent that a search has been made or that the information cited in the statement is, or is considered to be, material to patentability as defined in §1.56.

\boxtimes	This statement qualifies under 37 C.F.R. §1.97, subsection (b) because (check all that apply):						
		(1) than a	It is being filed within 3 months of the application filing date and is other continued prosecution application under § 1.53(d)				
		(2)	It is being filed within 3 months of entry of a national stage OR				
		(3) merits	It is being filed before the mail date of the first Office Action on the				

-- OR --

			before the mailing of a first Office Action after the filing ed examination under § 1.114.			
	filing d stage as action of	ate of a national application; (2) s set forth in §1.491 in an interna	being filed after the latest of: (1) three months beyond the three months beyond the date of entry of the national tional application; or (3) the mailing date of a first Officeing date of the earlier of a final office action under §1.113 nen:			
		a certification as specified in §1	.97(e) is provided below; or			
	a fee of \$180.00 as set forth in \$1.17(p) is authorized below, enclosed, or included with the payment of other papers filed together with this statement.					
	37 C.F.R. $\S1.97(d)$. If this statement is being filed after the mailing date of the earlier of a final office action under $\S1.113$ or a notice of allowance under $\S1.311$, but before payment of the issue fee, then:					
	A.	a certification as specified in §1	.97(e) is completed below; and			
	В.	a petition under 37 C.F.R. §1.97 submitted herewith; and	(d) requesting consideration of this statement is			
	C.	a fee of \$180.00 as set forth in \$ the payment of other papers file	1.17(i)(1) is authorized below, enclosed, or included with d together with this statement.			
\boxtimes	Fee Authorization. The Commissioner is hereby authorized to charge the above-referenced fees of \$0.00 and charge any additional fees or credit any overpayment associated with this communication to Deposit Account No. 08-1641 (Attorney's Docket No. 39780-2630 P1C4).					
			Respectfully submitted,			
Dated:	May 23	, 2005	By: Anna L. Barry (Reg. No. 51,436)			
TTIOT T	en ett					

HELLER EHRMAN LLP

275 Middlefield Road Menlo Park, CA 94025-3506 Telephone: (650) 324-7000 Facsimile: (650) 324-0638

Form PTO-1449		Attorney's Docket No.		Application Serial No.					
		39780-2630 P1C4	05	09/978,191					
INFORMATION DISCLOSURE STATEMENT			Applicant(s) Audrey GODDARD, et al.						
	•				Filing Date:		roup Art Unit:		
	(use se	veral sheets	if necessary)		October 15, 2001		346		
			Ţ,	J.S.	. PATENT DOCUMENTS				
Examiner	Ref.	Date	Document No.	T	lame .	Class	Subclass	Filing Date	
Initials	No.			1				(if appropri	iate)
	L			<u></u>		1		<u> </u>	
		1 = 4		_	GN PATENT DOCUMENTS	T 21			
Examiner Initials	Ref. No.	Date	Document No.	'	łame	Class	Subclass	Transla	
initials	NO.			╀		-		YES	NO
				╁					
				+-		-	-	 	
	<u>l</u>	1		<u>ل</u>	OTHER DOCUMENTS		<u> </u>	<u> </u>	L
			(including		hor, title, date, pertinent pages, etc.)			in the second of	e de la companya de l
Examiner	Ref.	Title	(including)	aut	nor, title, date, pertinent pages, etc./			<u> </u>	•
Initials	No.	''''							
	1.	Hanna, J.S. (1999).	., et al., "HER-2/neu Brea	ast	Cancer Predictive Testing", Oathology	Associa	tes Medical La	boratores, Au	ıgust
	2. Hyman, E., et al., "Impace of DNA Amplification on Gene Expression Patterns in Breast Cancer ^{1,2} ", Cancer Research – 62:6240-6245 (2002)						rch		
	3. Orntoft, T.F., et al., "Genome-wise Study of Gene Copy Numbers, Transcripts, and Protein Levels in Pairs of Non-invasive and Invasive Human Transitional Cell Carcinomas", Molecular & Cellular Proteomics – 1:37-45 (2002)						•		
4. Pollack, J.R., et al., "Microarray Analysis Reveals a Major Direct Role of DNA Copy Number Alteration in the Transcriptional Program of Human Breast Tumors", PNAS – 99(20):12963-12968 (2002)									
						`		·	
					-				
									
			· · · ·						
		ļ .							
									
• •									•
				-					
	ļ								
		ļ							
	 							<u>-</u>	
	<u> </u>	 	<u></u>		 	<u> </u>	us.		··
-			·		·				

	EXAMINER:	DATE CONSIDERED:				
	EXAMINER: Initial if citation considered, whether or not the citation conf	forms with MPEP 609. Draw a line through the citation if not in				
conformance and not considered. Include a copy of this form with next communication to applicant.						

*If an asterisk is placed beside the reference number, a copy is not provided because the reference was previously cited by or submitted to the PTO in a prior application that is identical in the statement and relied upon for an earlier filing date under 35 U.S.C. §120. 37 C.F.R. §1.98 (d).

SV 2126562 v1